Demand for VScan Dengue Fever Test Kits Increases
October 02 2007 - 6:21PM
PR Newswire (US)
EDMONTON, Alberta, Oct. 2 /PRNewswire-FirstCall/ -- Medical
Services International Inc. (Pink Sheets: MSITF) is pleased to
announce that the demand for its VScan Dengue Fever Kit is
increasing. Dengue Fever is spreading across Latin America and the
Caribbean in one of the worst outbreaks in decades causing
agonizing joint pain for hundreds of thousands of people and
killing 200 people so far this year. This year so far 630,356 cases
have been reported in the Americas and with the upcoming rainy
season, cases are expected to double. This does not take into
account the cases in SE Asia. The danger is that Doctors don't
recognize Dengue Fever. There are very few laboratories capable of
testing for Dengue Fever, and the ones available take up to 8 weeks
to complete the testing. By then it is too late for treatment.
There is no drug for Dengue Fever but early diagnosis resulting in
proper treatment including rest, IV fluids and pain relief can
reduce death rates to about 1%. Dengue Fever is mosquito borne and
is starting to spread into the southwestern United States. The
VScan Dengue Fever kit gives results in under 20 minutes and is
accurate greater than 99% of the time. Early diagnosis with the
VScan Dengue Fever kit allows for immediate treatment and reduces
the severity and convalescence of the Dengue Fever patient. Medical
Services International Inc. trades in the United States on the NQB
Pink Sheets under the symbol "MSITF". For further information,
please contact Robert Talbot at (780) 430 6363 or
http://www.medicalservicesintl.com/ or
http://www.minerva-biotech.com/. NOTE: Certain statements in this
press release are "forward-looking statements" within the meaning
of the Private Securities Act of 1995. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause results to differ materially. Such risks, uncertainties and
other factors include but are not limited to new economic
conditions, risk in product development, market acceptance of new
products and continuing product demand, level of competition and
other factors described in Company reports and other filings with
regulatory bodies. DATASOURCE: Medical Services International Inc.
CONTACT: Robert Talbot, +1-780-430-6363, for Medical Services
International Inc. Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/
Copyright